The Framingham steatosis index (FSI) was developed by Long et al. utilizing data from 1,181 participants of the Framingham Third Generation Cohort, which incorporated variables such as age, sex, BMI, TG, hypertension, diabetes, and the alanine aminotransferase (ALT) to aspartate aminotransferase (AST) ratio, yielding an AUC of 0.845 (10). The gene discussed is GPT; the disease is steatosis.